TerminatedPhase 4ketamine

Intraoperative Methadone Administration for Improved Pain Control in Spinal Fusion Patients

Sponsored by Montefiore Medical Center

NCT ID
NCT02989597
Target Enrollment
10 participants
Start Date
2017-07-29
Est. Completion
2020-11-10

About This Study

Methadone has several advantages over standard narcotic medications, especially when considering use after a typically painful surgery such as lumbar fusion. Methadone is low cost, has a long half-life, has a convenient dosing schedule, has excellent oral bioavailability, and demonstrates slow onset to withdrawal. The literature comparing methadone to more commonly used post-operative narcotics demonstrates that it manages pain better, sustains consistent plasma concentrations, decreases overall narcotic requirement, results in no additional adverse events, and is safe, even in children, across several studies. Since the standard of care is non-methadone narcotic usage to manage the significant pain of complex spinal surgery cases, it is understandable that methadone could be a desirable alternative to promote sustained pain control and early ambulation in these patients. The goal of this study is to compare the effect of a single dose of methadone administered intraoperatively in enrolled spinal fusion patients to their historical controls given fentanyl and morphine, and determine if more sustained pain control during the first few days after surgery provides a better subjective experience for the patient with less pain, which allows them to ambulate and leave the hospital sooner than patients given a standard regimen.

Conditions Studied

Pain, Postoperative

Interventions

  • Methadone Hydrochloride
  • Standard pain regimen
  • Spinal Fusion Surgery
  • Dexamethasone
  • Ketamine
  • Remifentanil
  • Sufentanil

Eligibility

Age:18 Years - 80 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria:

* Meets age criteria, age between 18-80
* Undergoing lumbar fusion surgery, one or two spinal levels
* ASA (American Society of Anesthesiologists) grades I-III

Exclusion Criteria:

* Patient outside of age criteria
* Renal failure requiring dialysis
* Serum creatinine greater than 2.0
* Hepatic dysfunction with liver function tests greater than twice the upper limit
* Pulmonary disease requiring home oxygen therapy
* Obstructive sleep apnea
* Severe heart disease
* Allergy to methadone, morphine, or fentanyl
* Recent or distant history of opioid abuse
* Poorly managed psychiatric illness
* Known history of alcohol abuse
* Morbid obesity (body mass index \> 50 kg/m2)
* Treatment with other NMDA receptor antagonists
* Prolonged QTc (corrected QT interval) on pre-operative EKG,
* Refusal or inability to sign the consent form
* Current use of HIV-1 protease inhibitors, erythromycin, ketoconazole, rifabutin, carbamazepine, phenytoin, phenobarbital, St. John's Wort, fluconazole, fluvoxamine, fluoxetine, paroxetine
* Grapefruit juice intake within the last week

Study Locations (1)

Montefiore Medical Center
The Bronx, New York, United States

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source